RecruitingNCT05880537
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
Safety, Efficacy, & Use of Decellularized Femoral Artery Allograft for Arteriovenous Access for Hemodialysis: A Multi-center Prospective Registry Study
Sponsor
LifeNet Health
Enrollment
100 participants
Start Date
Jun 6, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Be male or female, ≥18 years of age at the time of graft placement
- Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
- Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
- Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written informed consent/assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
- Have provided written authorization for use and disclosure of protected health information
Exclusion Criteria6
- Be participating in a study of another investigational drug or device
- Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
- Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
- Have a history or evidence of severe peripheral vascular disease in the upper extremities
- Have the inability or be unable or unwilling to follow the study visit schedule
- Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Interventions
OTHERNexeon Arterial Venous Allograft
Nexeon AVX allograft for hemodialysis access in end stage renal disease
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05880537
Related Trials
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT0463491617 locations
CAPABLE Transplant
NCT063269051 location
Solv Multi-Pass Hemodialysis System In-Center Clinical Study
NCT072168851 location
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
NCT070208321 location
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
NCT057265265 locations